Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Lymecycline 300mg Capsules versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecycline 300mg Capsules in the Treatment of Moderate to Severe Acne Vulgaris. - TEAM - Tetralysal Epiduo= Acne Makeover

GALDERMA R & D SNC0 个研究点目标入组 360 人开始时间: 2009年5月12日最近更新: 2012年3月19日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 360

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Male or female Subjects of any race, aged 12 to 35 years inclusive, 2.Subjects with moderate to severe facial acne vulgaris (Investigator?s Global Assessment score of 3 or 4), 3.Subjects with a minimum of 20 Inflammatory Lesions (papules and pustules) on the face, excluding the nose, 4.Subjects with a minimum of 30 and a maximum of 120 Non-Inflammatory Lesions (open comedones and closed comedones) on the face, excluding the nose, 5.Female Subjects of childbearing potential with a negative urine pregnancy test at the Baseline visit and must practice a highly effective method of contraception during the study: oral/systemic [injectable, patch?] contraception (must have been on a stable dose for 3 months prior to study entry), Intrauterine Device, strict abstinence, condoms, diaphragms, sponge, spermicides or partner had a vasectomy, 6.Females of non-childbearing potential, i.e., premenses, post-menopausal (absence of menstrual bleeding for 2 years), hysterectomy, bilateral tubal ligation, or bilateral ovariectomy, secondary infertility and sterility are not required to have a UPT at the beginning of the study, 7.Subjects have to read and sign the approved the Informed Consent form prior to any participation in the study. Subjects under the majority must sign an assent-to-participate form to participate in the study and they must have one parent or guardian read and sign the Informed Consent form prior to any study related procedure, 8.Subjects willing and capable of cooperating to the extend and degree required by the protocol
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•1.Subjects with more than 3 nodules or cysts on the face 2.Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), 3.Female Subjects who are pregnant, nursing or planning a pregnancy during the study, 4.Subjects with a wash-out period for topical treatment on the face less than (see table below): Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatments 2 weeks Zinc containing drugs 1 week Phototherapy devices for acne and cosmetic procedures: 1 week 5.Subjects with a wash-out period for systemic treatment less than (see table below): Acne therapy containing zinc 4 weeks Corticosteroids, antibiotics 4 weeks Other acne treatments (including isotretinoin and hormonal contraceptives solely for control of acne) 6 months Ciproterone acetate / Chlormadinone acetate 6 months Spironolactone / Drospirenone 3 months 6.Subjects with known impaired hepatic or renal functions. 7.Subjects with known intolerance to lactose. 8.Subjects with a condition or who are in a situation which, in the Investigator?s opinion, may put the Subject at risk (e.g. history of significant renal disease with impairment of renal function), may confound the study results, or may interfere with the Subject?s participation in the study, 9.Subjects who are at risk in terms of precautions, warnings, and contraindications (see package insert and/or Investigator brochure), 10.Subjects with known or suspected allergy to one of the investigational products (see package insert and/or investigator brochure), 11.Subjects who have participated in another investigational drug or device research study within 30 days of enrollment, 12.Subjects with a beard or other facial hair that might interfere with study assessments, 13.Adult Subjects under guardianship, hospitalised Subjects in a public or private institution for a reason other than the Research, and Subjects deprived of their freedom. 14.Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc...).

研究者

发起方

GALDERMA R & D SNC

相似试验

进行中（未招募）

不适用

Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Lymecycline 300mg Capsules versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecycline 300mg Capsules in the Treatment of Moderate to Severe Acne Vulgaris. - TEAM - Tetralysal Epiduo = Acne MakeoverModerate to severe acne vulgaris on the faceMedDRA version: 9.1Level: LLTClassification code 10000519Term: Acne vulgaris

EUCTR2008-006792-68-SEGalderma Research & Development360

进行中（未招募）

1 期

EUCTR2008-006792-68-FRGalderma Research & Development360

进行中（未招募）

不适用

EUCTR2008-006792-68-BEGalderma Research & Development360

进行中（未招募）

不适用

EUCTR2008-006792-68-DEGalderma Research & Development360

尚未招募

3 期

Efficacy and Safety Comparison of two different topical gels (one active and one vehicle) in combination with an oral antibiotic in the treatment of Moderate to Severe Acne Vulgaris.Skin - Dermatological conditionsAcne

ACTRN12609000443291Galderma Australia Pty Ltd360